An enveloped virus designates the virion having a lipid bilayer membrane, which plays important role in mediating virus fusion with and entry into the host cell. According to the structure of viral membrane fusion protein, enveloped viruses can be divided into classes I, II, and III. Class I and II adopt a common postfusion hairpin-like arrangement, juxtaposing the target-membrane insertion element of the protein with its viral transmembrane anchor, suggesting that they display similar mechanisms for catalyzing the membrane fusion reaction. Class I includes Retroviridae (e.g., HIV), Orthomyxoviridae (e.g., influenza virus), Paramyxoviridae (e.g., respiratory syncytial virus), Filoviridae (e.g., Ebola virus), and Coronaviridae (e.g., SARS-CoV and SARS-CoV-2), while class II includes Flaviviruses (e.g., Zika virus and dengue virus), Alphaviruses (e.g., chikungunya virus), and Bunyaviridae. The outbreaks of infectious diseases caused by class I and II enveloped viruses, such as AIDS, influenza, SARS, Ebola, Dengue fever, Zika, and COVID-19, have posed a serious threat to global public health, thus calling for the research and development of safe and effective vaccines and antivirals for prevention and treatment of these highly pathogenic infectious diseases.
This Research Topic is focused on the research and development of safe and effective vaccines and antivirals for the prevention and treatment of the highly pathogenic infectious diseases caused by the class I and II enveloped viruses, such as COVID-19, Ebola, AIDS, influenza, Zika, and dengue fever.
We welcome submissions of Original Research (basic studies, clinical studies) and Review articles on recent advances in our understanding of vaccines and therapeutics against class I and class II enveloped viruses. Topics may include, but are not limited to:
1. Identification of new molecular targets for the development of prophylactics and therapeutics against class I and II enveloped viruses.
2. All vaccine-related aspects, including novel approaches to vaccine development, vaccine efficacy, effectiveness, safety, adjuvant formulations, delivery strategies, and immunity studies to the development of novel vaccines.
3. All antivirals, varying from neutralizing antibodies to protein-, peptide-, small molecule-based therapeutic and prophylactic drugs or drug candidates.
An enveloped virus designates the virion having a lipid bilayer membrane, which plays important role in mediating virus fusion with and entry into the host cell. According to the structure of viral membrane fusion protein, enveloped viruses can be divided into classes I, II, and III. Class I and II adopt a common postfusion hairpin-like arrangement, juxtaposing the target-membrane insertion element of the protein with its viral transmembrane anchor, suggesting that they display similar mechanisms for catalyzing the membrane fusion reaction. Class I includes Retroviridae (e.g., HIV), Orthomyxoviridae (e.g., influenza virus), Paramyxoviridae (e.g., respiratory syncytial virus), Filoviridae (e.g., Ebola virus), and Coronaviridae (e.g., SARS-CoV and SARS-CoV-2), while class II includes Flaviviruses (e.g., Zika virus and dengue virus), Alphaviruses (e.g., chikungunya virus), and Bunyaviridae. The outbreaks of infectious diseases caused by class I and II enveloped viruses, such as AIDS, influenza, SARS, Ebola, Dengue fever, Zika, and COVID-19, have posed a serious threat to global public health, thus calling for the research and development of safe and effective vaccines and antivirals for prevention and treatment of these highly pathogenic infectious diseases.
This Research Topic is focused on the research and development of safe and effective vaccines and antivirals for the prevention and treatment of the highly pathogenic infectious diseases caused by the class I and II enveloped viruses, such as COVID-19, Ebola, AIDS, influenza, Zika, and dengue fever.
We welcome submissions of Original Research (basic studies, clinical studies) and Review articles on recent advances in our understanding of vaccines and therapeutics against class I and class II enveloped viruses. Topics may include, but are not limited to:
1. Identification of new molecular targets for the development of prophylactics and therapeutics against class I and II enveloped viruses.
2. All vaccine-related aspects, including novel approaches to vaccine development, vaccine efficacy, effectiveness, safety, adjuvant formulations, delivery strategies, and immunity studies to the development of novel vaccines.
3. All antivirals, varying from neutralizing antibodies to protein-, peptide-, small molecule-based therapeutic and prophylactic drugs or drug candidates.
